NCT06624644: An ongoing trial by Linnaeus Therapeutics, Inc.
This trial is ongoing. It must report results 4 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06624644 |
|---|---|
| Title | A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 6, 2025 |
| Completion date | Feb. 28, 2029 |
| Required reporting date | Feb. 28, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |